Promega Corp v. Life Tech, No. 13-1011 (Fed. Cir. Dec. 15, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Life Technologies, Applied Biosystems, LLC, and Invi- trogen IP Holdings, Inc. (collectively, LifeTech) appeal from the district court’s grant of a motion for summary judgment that the asserte d claims of United States P a- tent Nos. 5,843,660 (’660 patent), 6,221,598 (’598 patent), 6,479,235 (’235 patent) , and 7,008,771 (’771 patent) (co l- lectively, the Promega patents) are not invalid for lack of enablement and obviousness . Promega Corp. and M ax- Planck-Gesellschaft zur F örderung der Wissen schaften E.V.